Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma.
about
Gene expression patterns in ovarian carcinomasDietary fat intake and ovarian cancer risk: a meta-analysis of epidemiological studiesIdentification of novel therapeutic targets in microdissected clear cell ovarian cancersRsf-1 (HBXAP) expression is associated with advanced stage and lymph node metastasis in ovarian clear cell carcinoma.Pathogenesis of ovarian clear cell adenofibroma, atypical proliferative (borderline) tumor, and carcinoma: clinicopathologic features of tumors with endometriosis or adenofibromatous components support two related pathways of tumor developmentIntegrative bioinformatics links HNF1B with clear cell carcinoma and tumor-associated thrombosis.Clusterin is a potential molecular predictor for ovarian cancer patient's survival: targeting clusterin improves response to paclitaxel.Ovarian clear cell adenocarcinoma: a continuing enigmaMetabolic alterations caused by HNF1β expression in ovarian clear cell carcinoma contribute to cell survivalClear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging.Pathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms.Clear cell carcinomas of the ovary: a mono-institutional study of 73 cases in China with an analysis of the prognostic significance of clinicopathological parameters and IMP3 expression.Telomere length in different histologic types of ovarian carcinoma with emphasis on clear cell carcinoma.Circulating intercellular adhesion molecule 1 (ICAM-1), E-selectin and vascular cell adhesion molecule 1 (VCAM-1) in head and neck cancer.New perspectives on molecular targeted therapy in ovarian clear cell carcinoma.Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma.Expression of membrane type 1 matrix metalloproteinase (MMP-14) in epithelial ovarian cancer: high level expression in clear cell carcinoma.Patterns of spread of clear cell ovarian cancer: Case report and case series.Targeting annexin A4 to counteract chemoresistance in clear cell carcinoma of the ovary.Class III b-tubulin overexpression in gynecologic tumors: implications for the choice of microtubule targeted agents?Suppression of cellular invasion by glybenclamide through inhibited secretion of platelet-derived growth factor in ovarian clear cell carcinoma ES-2 cells.Expression of angiogenic chemokines in ovarian clear cell carcinoma.Microlaparoscopic left upper quadrant entry in patients at high risk of periumbilical adhesions.Evidence for ethnic and environmental contributions to frequency of ovarian clear cell carcinoma.Clinicopathological characteristics of ovarian carcinomas associated with endometriosis.Prognostic significance of histological grade in clear-cell carcinoma of the ovary: a retrospective study of Korean Gynecologic Oncology Group.HER2 is frequently over-expressed in ovarian clear cell adenocarcinoma: possible novel treatment modality using recombinant monoclonal antibody against HER2, trastuzumab.Prognostic Role of Neutrophil to Lymphocyte Ratio in Ovarian Cancer: A Meta-Analysis
P2860
Q24644996-B6EA0A9F-E5EC-4DBE-AE3D-61125C845BAEQ26749395-AA99FB31-1027-43BA-9CFB-F477228B1099Q28742873-38D480DB-A49F-424E-AD94-DDADB685D4F2Q34643587-BF770119-9B2C-4A2A-B29E-93B9EFFB704DQ34771886-211B027E-B429-494E-A7FE-C024B3C024C7Q34990141-B950F55F-9F05-4353-8400-AEF6EFC6FAF0Q35780679-480E115B-5E0C-429B-B285-ABD213D54353Q36026090-77E392A2-6058-48F0-9574-26D0B0C8A3DAQ36413347-1C09C0E0-1D00-4FD5-9EED-0CEF25D4A696Q36461591-65CEB918-BE16-42FF-92E7-F498F2BFBCA4Q36469640-C5400257-503B-492D-A8CF-A8B40E27FFB1Q36529643-EFD193E8-5247-4DAF-A292-BA3AFCD88105Q36608043-4DE50D74-374C-4E77-B59F-AB1CFFE266F0Q36617374-4F04C373-CF77-4C61-B19E-08800EC585E0Q36889642-00D7D78C-A5F2-4E94-827F-F7566CC90482Q37123500-DEAD53AE-B73A-4F2A-8E94-E2E2E2FFEAD7Q37145551-5FA7EB57-A14C-4086-ADD2-08FC3079A087Q37390108-A1B5F8B3-F818-4133-9C3F-8E588077278AQ37776738-6854DCEC-4A0F-4050-A1E3-7A648E8C3371Q38069185-AA9D67C3-8D2F-470A-B13D-4BA6B6620AFFQ39335926-7BD1FD8A-6320-4EF6-9907-676D4176A5C4Q39577538-CB7FDD04-1835-4CFE-B049-F57A62262951Q40819577-3FD4A29B-ACE4-4A4A-B324-7E4C4F43F094Q44400581-26DD9826-0282-4540-AAB3-0390AAC65296Q45028382-9E97C669-7DFC-45AC-9DBE-9CA02CFFE8B8Q53517417-AEADBD4B-2C14-44FE-AE4F-C31C0FC9D749Q55090683-A463F0DA-F411-41EC-AA75-647B7B68CB34Q58701119-0B6A0E4E-7AD2-4CA5-8954-E40634146C1D
P2860
Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
1989年论文
@zh
1989年论文
@zh-cn
name
Clear cell adenocarcinoma of t ...... parison with serous carcinoma.
@en
type
label
Clear cell adenocarcinoma of t ...... parison with serous carcinoma.
@en
prefLabel
Clear cell adenocarcinoma of t ...... parison with serous carcinoma.
@en
P2093
P1433
P1476
Clear cell adenocarcinoma of t ...... parison with serous carcinoma.
@en
P2093
Griffiths CT
Jenison EL
P356
10.1016/0090-8258(89)90852-4
P407
P577
1989-01-01T00:00:00Z